Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • (S)-Mephenytoin: Benchmark CYP2C19 Substrate for Organoid...

    2026-02-09

    (S)-Mephenytoin: Benchmarking CYP2C19 Substrate for Advanced Organoid Pharmacokinetics

    Principle and Setup: The Role of (S)-Mephenytoin in CYP2C19-Driven Drug Metabolism

    The accurate modeling of human drug metabolism is a linchpin in pharmacokinetic studies, drug discovery, and toxicity profiling. Central to these processes is the cytochrome P450 superfamily—particularly CYP2C19, a key enzyme involved in the metabolism of diverse therapeutic agents. (S)-Mephenytoin has emerged as a gold-standard CYP2C19 substrate, recognized for its high specificity and well-defined kinetic parameters. As a prototypical anticonvulsive drug, (S)-Mephenytoin undergoes N-demethylation and aromatic 4-hydroxylation via CYP2C19 (also known as mephenytoin 4-hydroxylase), making it invaluable for assaying oxidative drug metabolism in vitro.

    The use of (S)-Mephenytoin is especially transformative in advanced human-relevant models, such as human induced pluripotent stem cell (hiPSC)-derived intestinal organoids. These organoids recapitulate the expression patterns and metabolic competence of native intestinal tissue, offering a powerful platform to study absorption, metabolism, and excretion with human fidelity (Saito et al., 2025).

    Step-By-Step Experimental Workflow: Integrating (S)-Mephenytoin into In Vitro CYP2C19 Assays

    1. Model Preparation: hiPSC-Derived Intestinal Organoids

    • Differentiate hiPSCs following established protocols to yield intestinal organoids containing mature enterocyte populations. Ensure organoids express CYP2C19 at physiologically relevant levels (Saito et al., 2025).
    • Transition organoids to 2D monolayer cultures if enhanced accessibility for substrate and inhibitor studies is required.

    2. Substrate Incubation

    • Prepare (S)-Mephenytoin stock solutions at up to 25 mg/mL in DMSO for maximum solubility; dilute appropriately in assay buffer to achieve target concentrations (commonly 10–1000 μM).
    • Incubate organoid-derived enterocytes or hepatic microsomes with (S)-Mephenytoin in the presence or absence of cytochrome b5 to evaluate its effect on metabolic turnover.
    • Maintain reactions at 37°C; typical incubation times range from 30 minutes to 2 hours, depending on endpoint sensitivity.

    3. Detection and Quantification

    • Terminate reactions using ice-cold acetonitrile or methanol to precipitate proteins.
    • Centrifuge samples and analyze supernatants for 4-hydroxy-mephenytoin (the principal oxidative metabolite) via LC-MS/MS or HPLC with UV detection.
    • Calculate kinetic parameters; in vitro studies have established a Km of 1.25 mM and Vmax values of 0.8–1.25 nmol/min/nmol P450 enzyme for CYP2C19-mediated 4-hydroxylation of (S)-Mephenytoin.

    4. Data Analysis

    • Plot substrate depletion or product formation over time to determine enzyme velocity and compare across experimental conditions (e.g., genetic polymorphisms, inhibitor presence).
    • Employ Michaelis–Menten kinetics to extract quantitative parameters, facilitating direct comparison with literature benchmarks.

    Advanced Applications & Comparative Advantages

    The integration of (S)-Mephenytoin into hiPSC-derived intestinal organoid workflows delivers several unique benefits for pharmacokinetic studies and drug metabolism research:

    • Human-Relevant CYP2C19 Profiling: Unlike animal models or traditional Caco-2 cells, organoid systems recapitulate native human CYP2C19 activity, making (S)-Mephenytoin assays more predictive of in vivo outcomes (Saito et al., 2025).
    • Precision Medicine Applications: By leveraging organoids from donors with distinct CYP2C19 genotypes (e.g., *1/*1, *2/*2, *17 carriers), researchers can characterize genotype-phenotype correlations and predict metabolic variability relevant to clinical practice.
    • Translational Insight: As highlighted in (S)-Mephenytoin: A Benchmark CYP2C19 Substrate for Human In Vitro Models, this substrate remains the reference standard for validating new organoid and microphysiological systems, enabling direct comparison and model harmonization across the field.
    • Multiplexing and Drug-Drug Interaction Studies: (S)-Mephenytoin’s selective metabolism by CYP2C19 allows for the systematic assessment of competitive and non-competitive inhibitors, induction protocols, and transporter interplay, supporting regulatory-grade DDI studies.

    These capabilities are further extended in the article (S)-Mephenytoin in Next-Generation CYP2C19 Pharmacokinetics, which explores the mechanistic nuances and translational impact of incorporating (S)-Mephenytoin into organoid-based assays, complementing the core workflow described above.

    Troubleshooting and Optimization: Best Practices for Robust Data

    Even with a highly characterized substrate like (S)-Mephenytoin, optimizing experimental outcomes requires attention to protocol details and awareness of potential pitfalls:

    • Solubility and Stability: While (S)-Mephenytoin is soluble up to 25 mg/mL in DMSO or dimethylformamide, precipitation may occur if diluted rapidly into aqueous media. Always pre-warm and mix thoroughly to ensure homogeneity. Prepare fresh solutions for each experiment, as even brief storage at room temperature can compromise substrate integrity.
    • Enzyme Expression Variability: Monitor CYP2C19 mRNA and protein levels in organoid cultures using qPCR and immunoblotting. Batch-to-batch variation in differentiation efficiency can impact metabolic rates; standardize differentiation protocols and passage numbers for reproducibility.
    • Assay Sensitivity: Optimize LC-MS/MS or HPLC conditions to detect low levels of 4-hydroxy-mephenytoin, especially when working with low-expressing CYP2C19 variants. Employ stable isotope-labeled internal standards where possible.
    • Genetic Polymorphism Controls: Include organoids from multiple donors or engineered lines representing key CYP2C19 allelic variants to distinguish enzyme-specific metabolic differences, as described in (S)-Mephenytoin: CYP2C19 Substrate for Precision Drug Metabolism.
    • Substrate Concentration: Maintain substrate concentrations within the linear range of enzyme kinetics (typically ≤ Km) to avoid saturation and ensure meaningful velocity measurements.
    • Negative and Positive Controls: Run vehicle and known inhibitor controls (e.g., omeprazole for CYP2C19) alongside samples to confirm specificity and detect off-target activity.

    For an applied, scenario-based troubleshooting guide, (S)-Mephenytoin (SKU C3414): Reliable CYP2C19 Substrate for Pharmacokinetics offers detailed recommendations on assay design and vendor selection, underscoring the reliability of sourcing from APExBIO.

    Future Outlook: Expanding the Impact of (S)-Mephenytoin in Drug Metabolism Research

    The deployment of (S)-Mephenytoin as a CYP2C19 substrate within hiPSC-derived intestinal organoids is rapidly redefining the landscape of preclinical drug metabolism studies. As organoid systems become more sophisticated—incorporating other cell types, vascularization, and immune components—the predictive value of (S)-Mephenytoin metabolism for human pharmacokinetics and interindividual variability will continue to rise.

    Emerging directions include:

    • Integration with Microphysiological Systems (MPS): Combining organoids with microfluidic platforms to simulate gut-liver axis dynamics, enabling systemic pharmacokinetic modeling and personalized medicine applications.
    • High-Throughput Screening: Automation of (S)-Mephenytoin-based CYP2C19 assays in 96- or 384-well plate formats for rapid compound library screening and drug-drug interaction profiling.
    • Regulatory Translation: As discussed in earlier resources, the use of benchmark substrates like (S)-Mephenytoin is expected to become standard in regulatory submissions and quality assurance for new in vitro models.

    For researchers seeking validated, high-purity compounds, APExBIO remains a trusted supplier of (S)-Mephenytoin (SKU C3414), ensuring batch-to-batch consistency and technical support tailored to cutting-edge pharmacokinetic inquiries.

    Conclusion

    (S)-Mephenytoin’s role as a reference CYP2C19 substrate is pivotal in bridging benchtop cytochrome P450 metabolism studies with translational pharmacokinetics and precision drug development. By leveraging its robust kinetic properties in hiPSC-derived organoids and advanced in vitro models, scientists can generate reproducible data that accelerate drug discovery and enable patient-tailored therapies.

    To incorporate (S)-Mephenytoin into your workflows or to explore technical details, visit the product page at APExBIO (S)-Mephenytoin.